• RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer Kim BR, Na YJ, Kim JL, et al. RUNX3 suppresses metastasis and stemness by inhibiting Hedgehog signaling in colorectal cancer. Cell Death Differ. 2020;27(2):676-694. doi:10.1038/s41418-019-0379-5 More View

• Korean Red Ginseng Extract Increases Apoptosis by Activation of the Noxa Pathway in Colorectal Cancer Jeong YA, Kim BR, Kim DY, et al. Korean Red Ginseng Extract Increases Apoptosis by Activation of the Noxa Pathway in Colorectal Cancer. Nutrients. 2019;11(9):2026. Published 2019 Aug 29. doi:10.3390/nu11092026 More View

• A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data Chen LT, Satoh T, Ryu MH, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23(3):510-519. doi:10.1007/s10120-019-01034-7 More View

• Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer Tabernero J, Ohtsu A, Muro K, et al. Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer. Mol Cancer Ther. 2017;16(10):2215-2222. doi:10.1158/1535-7163.MCT-16-0895 More View

• Deficiency of 15-LOX-1 Induces Radioresistance through Downregulation of MacroH2A2 in Colorectal Cancer Na YJ, Kim BR, Kim JL, et al. Deficiency of 15-LOX-1 Induces Radioresistance through Downregulation of MacroH2A2 in Colorectal Cancer. Cancers (Basel). 2019;11(11):1776. Published 2019 Nov 11. doi:10.3390/cancers11111776 More View

• Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safet… Satoh T, Kang YK, Chao Y, et al. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer. Gastric Cancer. 2020;23(1):143-153. doi:10.1007/s10120-019-00970-8 More View

• Novel Systemic Therapies for Advanced Gastric Cancer Kim HJ, Oh SC. Novel Systemic Therapies for Advanced Gastric Cancer. J Gastric Cancer. 2018;18(1):1-19. doi:10.5230/jgc.2018.18.e3 More View

• Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer Park SH, Jo MJ, Kim BR, et al. Sonic hedgehog pathway activation is associated with cetuximab resistance and EPHB3 receptor induction in colorectal cancer. Theranostics. 2019;9(8):2235-2251. Published 2019 Apr 12. doi:10.7150/thno.30678 More View

• Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of fi… Kang YK, Ryu MH, Park SH, et al. Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy. Ann Oncol. 2018;29(5):1220-1226. doi:10.1093/annonc/mdy055 More View

• PARK7 modulates autophagic proteolysis through binding to the N-terminally arginylated form of the molecular chaperone HSPA5 Lee DH, Kim D, Kim ST, et al. PARK7 modulates autophagic proteolysis through binding to the N-terminally arginylated form of the molecular chaperone HSPA5. Autophagy. 2018;14(11):1870-1885. doi:10.1080/15548627.2018.1491212 More View